Celgene Corporation Provides Earnings Guidance for the Year 2012 and 2013
The company announced that in 2013, total net product sales are expected to be approximately $6.0 billion, an 11.4% year-over-year increase. REVLIMID net sales are expected to be in the range of $4.1 billion to $4.2 billion, including approximately $90 million of negative year-over-year foreign exchange impact. Assuming constant foreign exchange, REVLIMID growth would be 11 to 14%. Adjusted diluted earnings per share is expected in the range of $5.50 to $5.60, a 12 to 14% year-over-year increase. Based on U.S. Generally Accepted Accounting Principles (GAAP), diluted EPS is expected in the range of $4.67 to $4.79.